{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:07:01Z","timestamp":1773799621452,"version":"3.50.1"},"reference-count":68,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T00:00:00Z","timestamp":1352160000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There are no direct comparisons of paliperidone extended\u2010release (ER), aripiprazole and ziprasidone in efficacy and metabolic influence in patients with first\u2010episode schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The present study examined the efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone in patients with first\u2010episode schizophrenia in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects were recruited from outpatient and 254 patients entered the trial. These patients received treatment randomly with paliperidone ER, aripiprazole and ziprasidone and were assessed at baseline, 13, 26 and 52\u2009weeks, respectively with Positive and Negative Syndrome Scale (PANSS), 7\u2010item Clinical Global Impressions\u2010Severity (CGI\u2010S), anthropometric (weight, body mass index and waist circumference) and metabolic (fasting blood glucose, HbA1c, cholesterol, high density lipoproteins (HDL), low density lipoproteins and triglycerides) measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 203 patients completed the trial. Paliperidone group had significant greater reduction in PANSS than aripiprazole group and ziprasidone group from 13\u2009weeks, although the a reduction in PANSS of each group was more than 20%. There was no difference in CGI\u2010S among the three groups, and all three groups had a significant reduction from baseline in CGI\u2010S. Aripiprazole group increased in weight and body mass index despite no statistical change in waist circumference. Other two groups showed no changes in anthropometric measure. At the end of the study, two glucose metabolic indices (fasting blood glucose and HbA1c) of aripiprazole group were significantly higher than that of baseline. In lipid metabolism, aripiprazole group reduced triglycerides significantly and had no changes in other indices. Paliperidone group reduced HDL and increased triglycerides despite no changes in glucose metabolism. Ziprasidone group also had no significant changes in glucose metabolism, but reduced cholesterol, low density lipoproteins and increased HDL. Furthermore, 22 subjects in three groups reached the diagnostic criteria of metabolic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Paliperidone ER, aripiprazole and ziprasidone are effective in treating first\u2010episode schizophrenia, and the ranking of efficacy from high to low is paliperidone ER\u2009&gt;\u2009aripiprazole\u2009&gt;\u2009ziprasidone. Paliperidone ER can impair lipid metabolism potentially but had no influence on glucose metabolism. Aripiprazole can damage glucose metabolism and has little influence on lipid metabolism. Ziprasidone is considered an atypical antipsychotic with no evidence of harm to glucose and lipid metabolism. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2270","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T06:18:54Z","timestamp":1352182734000},"page":"605-614","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first\u2010episode schizophrenia through 52\u2009weeks follow\u2010up in China"],"prefix":"10.1002","volume":"27","author":[{"given":"Yinbo","family":"Zhang","sequence":"first","affiliation":[{"name":"Chengdu Mental Health Center Fourth People's Hospital  Chengdu 610035 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangzhi","family":"Dai","sequence":"additional","affiliation":[{"name":"Chengdu Mental Health Center Fourth People's Hospital  Chengdu 610035 China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,6]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"233","article-title":"Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER","volume":"2","author":"Birnbaum M","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000352"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.613"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1344-3"},{"issue":"7","key":"e_1_2_7_6_1","first-page":"4","article-title":"Antipsychotic\u2010induced weight gain and metabolic abnormalities: implications for in\u2010creased mortality in patients with schizophrenia","volume":"65","author":"Casey DE","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01321.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132613"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216070-00004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.003"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.12.855"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.14.2307"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328314e1f3"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.052605"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1055"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.09.016"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721110-00004"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1102"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2008.10.005"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.06.003"},{"issue":"6","key":"e_1_2_7_22_1","first-page":"11","article-title":"Schizophrenia and comorbid metabolic disorders","volume":"66","author":"Henderson DC","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2005.00495.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"e_1_2_7_25_1","unstructured":"International Diabetes Federation.2005.IDF Consensus worldwide definition of the metabolic syndrome. International Diabetes Foundation: Belgium. Available from URL:http:\/\/www.idf.org\/webdata\/docs\/MetS_def_update2006.pdf[cited 3 October 2007]."},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/NDT.S1365","article-title":"A review of the clinical trial data","volume":"3","author":"Janicak P","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48383"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.09.012"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.12.265"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611417104"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3180a9076c"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200311000-00007"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.156.2.312","article-title":"Body weight and leptin plasma levels during treatment with antipsychotic drugs","volume":"156","author":"Kraus T","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2004.tb06443.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.02.007"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.075366"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0821a"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.01.017"},{"key":"e_1_2_7_41_1","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double\u2010blind study","volume":"65","author":"McQuade RD","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n1006"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0515"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001556"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.51.12.1528"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16458-1"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3180a76dc0"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.6.863"},{"issue":"1","key":"e_1_2_7_49_1","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer JW","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100803"},{"key":"e_1_2_7_51_1","first-page":"CD006369","article-title":"Oral paliperidone for schizophrenia","volume":"2","author":"Nussbaum AM","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.03.025"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000103868"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08913-4"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/1359786806066040"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2003.08.044"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1123"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.02.013"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10673220600748486"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02092.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.6.651"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60995-8"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2004.00141.x"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.03.014"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000095347.32154.08"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0602"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.6.771"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721050-00005"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2270","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:41:20Z","timestamp":1700599280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/hup.2270"],"URL":"https:\/\/doi.org\/10.1002\/hup.2270","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}